The Herald | HeraldOnline.comInsmed’s shares recover as analysts highlight positive trial dataReuters(Reuters) – Insmed Inc’s shares plunged after its experimental drug to treat a form of bacterial lung infection failed the main goal of a trial, but the stock clawed back much of its early losses after analysts said positive secondary data was more relevant. Insmed’s …Insmed Falls On Mixed Results For Lung Drug; Analysts Defend INSMInvestor’s Business DailyAhead of the Bell: Insmed shares sinkBusinessweekUPDATED: Insmed faces another setback as lead therapy flunks PhII lung studyFierceBiotechWall Street Journal -MarketWatch -Investorplace.comall 21 news articles …Read Full Story
Insmed's shares recover as analysts highlight positive trial data - Reuters
Real Estate of Cebu
